We are delighted to present the return of our 9th Annual
RNA Therapeutics conference to London on the 21st - 22nd February 2018.
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the
RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in
RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and evaluate with key industry leaders the lessons they've learnt whilst developing an
RNA therapeutic.
Join us this February 2018, as our
RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to analyze and evaluate the latest advancements including SaRNA as a potential therapeutic for people with liver cancer, advances in targeted delivery of nucleotides beyond the liver and the latest developments in delivery systems, such as exosomes and nanocomplexes
Some Featured Highlights will include:
- Hear from MiNA Therapeutics about their new pre-clinical data supporting the on-target mechanism of action of their pioneering new drug candidate MTL-CEBPA
- Learn how CureVac's sophisticated technologies and approaches have helped overcome limitations such as the instability of single-stranded RNA
- Discover STORM Therapeutics' innovative approach: Harnessing the power of RNA epigenetics to develop first-inclass drugs in oncology
- Expand your knowledge of patenting RNA Therapeutics, with James Ogle, a European and UK Chartered Patent Attorney with particular expertise in RNA and other nucleic acid based technologies
- Examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches
Speakers
- Birgit Pless, Deputy Head of Project Management, BioNTech AG
- Bob Brown, CSO and SVP Research & Development, Dicerna Pharmaceuticals Inc.
- David Giljohann, CEO, Exicure Inc.
- Ekkehard Leberer, Senior Director , Sanofi
- Elena Bichenkova, Senior Lecturer in Medicinal Chemistry, Manchester University
- Giulietta Maruggi, Lab Head, Vector Biology, GSK
- Helen McCarthy, Chair of Nanomedicine, Queen’s University Belfast’s, School of Pharmacy
- James Ogle, European Patent Attorney and UK Chartered Patent Attorney, Hoffmann Eitle
- James Hamilton, Vice President Clinical Development, Arrowhead Pharmaceuticals, Inc.
- Kai Wilkens, Senior Director Europe, Advanced Cell Diagnostics SRL
- Kirsty Wydenbach, Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, Medicines and Healthcare products Regulatory Agency
- Mariola Fotin-Mleczek, Chief Scientific Officer., CureVac GmbH
- Markus Mandler, Chief Scientific Officer, Accanis
- Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics
- Noreen Henig, Chief Medical Officer, ProQR Therapeutics BV
- Oliver Rausch, VP Research & Development , Storm Therapeutics
- Paul Agris, Founding Director, The RNA Institute, SUNY University at Albany
- Samir EL Andaloussi, Assistant Professor , Karolinska Institutet
- Shalini Andersson, Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D
- Steffen Panzner, Managing Director, Lipocalyx
- Stephen Hart, Professor in Molecular Genetics, University College London
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Holiday Inn Kensington Forum
97 Cromwell Rd, Kensington, SW7 4DN
London, UK
Who should attend
Key Job Titles include:
- Research & Development Directors/Managers/Scientists
- Senior Scientists
- Chief Scientific Officers
- Chief Medical Officers
- Heads of Clinical Development
- Heads of Pre-Clinical Development
Global Presence:
- Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.
Venue
Holiday Inn Kensington Forum97 Cromwell Road,
London, United Kingdom
